Chiesi Farmaceutici S.p.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chiesi Farmaceutici S.p.A.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Plus recent deals involving BeiGene, Assembly Biosciences, Piramal, Medivant, Revitope, Junshi, JW Therapeutics, Eureka, Acepodia, Chiesi, Bayer, NewG Lab, AnHeart
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
FDA may be evaluating the future of accelerated approval, but data from the Pink Sheet’s Performance Tracker shows growth in the submissions and approvals over the past five years.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Cornerstone Therapeutics (Cardiokine, Inc.
- Critical Therapeutics, Inc.
- EKR Therapeutics Inc.)
- Torrex Chiesi Pharma
- Zymenex Holding A/S
- Atopix Therapeutics Limited